SYRS investors have the opportunity to join Syros Pharmaceuticals, Inc. Securities Fraud Investigation with the Schall Law Firm

Schall Law Firm, a national law firm focused on shareholder rights litigation, announces that it is investigating claims alleging violations of the securities laws on behalf of investors of Syros Pharmaceuticals, Inc. (“Syros” or “the Company”) (NASDAQ: SYRS).

The investigation focuses on whether the company made false and/or misleading statements and/or failed to disclose information relevant to investors. Syros issued a press release on August 12, 2024, in which it “announced that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unsuitable patients with acute myeloid leukemia (AML) and overexpression of the RARA gene.” According to the company, the “decision is based on the results of a pre-specified interim analysis of the trial,” and the analysis that “the likelihood of success . . . to demonstrate superiority at the final analysis . . . was considered low.”